Literature DB >> 31984805

Insights into gastrointestinal microbiota-generated ginsenoside metabolites and their bioactivities.

Li Yang1,2,3,4, Hecun Zou1,2,3,4,5, Yongchao Gao1,2,3,4, Junjia Luo1,2,3,4, Xiaonv Xie1,2,3,4, Wenhui Meng1,2,3,4, Honghao Zhou1,2,3,4, Zhirong Tan1,2,3,4.   

Abstract

The gastrointestinal microbiota and host co-evolve into a complex 'super-organism,' and this relationship plays a vital role in many physiological processes, such as drug metabolism. Ginseng is an important medicinal resource and the main ingredients are ginsenosides, which are less polar, difficult to absorb, and have low bioavailability. However, studies have shown that the biological activity of ginsenosides such as compound K (CK), ginsenoside Rg3 (Rg3), ginsenoside Rh2 (Rh2), 20(S)-protopanaxatriol (20(S)-PPT), and 20(S)-protopanaxadiol (20(S)-PPD) is closely related to the gastrointestinal microbiota. In this paper, the metabolic pathway of gastrointestinal microbiota-generated ginsenosides and the main pharmacological effects of these metabolites are discussed. Furthermore, our study provides a new insight into the discovery of novel drugs. Specifically, in new drug screening process, candidates with low biological activity and bioavailability should not be excluded. Because their metabolites may exhibit good pharmacological effects due to the involvement of the gastrointestinal microbiota. In addition, in further research studies to develop probiotics, a combination of agents could exert greater efficacy than single agents. Moreover, differences in lifestyle and diet lead to differences in the gastrointestinal microbiota in the human body. Therefore, administration of the same drug dose to different individuals could elicit different therapeutic effects, owing to the involvement of the gastrointestinal microbiota. Thus, treatment accuracy could be achieved by detecting the gastrointestinal microbiota before drug treatment.HighlightsGastrointestinal microbiota plays a decisive role in bioactivities of ginsenosides.The metabolic pathway and main pharmacological effects of ginsenoside metabolites are discussed.It provides new insights into novel drug discovery and further research to find probiotic, combinations to exert greater efficacy.Differences in lifestyle and diet, varies the gastrointestinal microbiota in the human body. However, the same dose of a drug producing different therapeutic effects may involve gastrointestinal microbiota.

Entities:  

Keywords:  Gastrointestinal microbiota; ginsenosides; metabolic pathway; metabolite bioactivity; super-organism

Mesh:

Substances:

Year:  2020        PMID: 31984805     DOI: 10.1080/03602532.2020.1714645

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  11 in total

1.  Ginsenoside Rh2 Inhibits NLRP3 Inflammasome Activation and Improves Exosomes to Alleviate Hypoxia-Induced Myocardial Injury.

Authors:  Zhongwen Qi; Zhipeng Yan; Yueyao Wang; Nan Ji; Xiaoya Yang; Ao Zhang; Meng Li; Fengqin Xu; Junping Zhang
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

2.  Korean Red Ginseng and Ginsenoside Rg3 Suppress Asian Sand Dust-Induced Epithelial-Mesenchymal Transition in Nasal Epithelial Cells.

Authors:  Seung-Heon Shin; Mi-Kyung Ye; Dong-Won Lee; Mi-Hyun Chae; You-Jin Hwang
Journal:  Molecules       Date:  2022-04-20       Impact factor: 4.927

Review 3.  Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation.

Authors:  Zhaoqiang Chen; Zepeng Zhang; Jiaqi Liu; Hongyu Qi; Jing Li; Jinjin Chen; Qingxia Huang; Qing Liu; Jia Mi; Xiangyan Li
Journal:  Front Cell Infect Microbiol       Date:  2022-04-25       Impact factor: 6.073

4.  Effect of Fermented Red Ginseng Concentrate Intake on Stool Characteristic, Biochemical Parameters, and Gut Microbiota in Elderly Korean Women.

Authors:  Songhee Lee; Sunghee Jung; Heesang You; Yeongju Lee; Youngsook Park; Hyunkoo Lee; Sunghee Hyun
Journal:  Nutrients       Date:  2022-04-19       Impact factor: 6.706

5.  Differences in Intestinal Metabolism of Ginseng Between Normal and Immunosuppressed Rats.

Authors:  Jin-Hao Zhu; Jin-Di Xu; Shan-Shan Zhou; Xiao-Ya Zhang; Jing Zhou; Ming Kong; Qian Mao; He Zhu; Song-Lin Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-01       Impact factor: 2.441

Review 6.  Ginsenoside Compound K: Insights into Recent Studies on Pharmacokinetics and Health-Promoting Activities.

Authors:  Anshul Sharma; Hae-Jeung Lee
Journal:  Biomolecules       Date:  2020-07-10

7.  Ginsenoside M1 Induces Apoptosis and Inhibits the Migration of Human Oral Cancer Cells.

Authors:  Yu-Chieh Lee; Wei-Ting Wong; Lan-Hui Li; Lichieh Julie Chu; Mridula P Menon; Chen-Lung Ho; Oleg V Chernikov; Sheau-Long Lee; Kuo-Feng Hua
Journal:  Int J Mol Sci       Date:  2020-12-19       Impact factor: 5.923

8.  Targeting PLA2G16, a lipid metabolism gene, by Ginsenoside Compound K to suppress the malignant progression of colorectal cancer.

Authors:  Li Yang; Lingjie Zheng; Xiaonv Xie; Junjia Luo; Jing Yu; Lihua Zhang; Wenhui Meng; Yingen Zhou; Ling Chen; Dongsheng Ouyang; Honghao Zhou; Zhirong Tan
Journal:  J Adv Res       Date:  2021-06-12       Impact factor: 10.479

9.  Positive influence of gut microbiota on the effects of Korean red ginseng in metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Eunhak Seong; Shambhunath Bose; Song-Yi Han; Eun-Ji Song; Myeongjong Lee; Young-Do Nam; Hojun Kim
Journal:  EPMA J       Date:  2021-06-03       Impact factor: 8.836

Review 10.  Potential Modulatory Microbiome Therapies for Prevention or Treatment of Inflammatory Bowel Diseases.

Authors:  Daan V Bunt; Adriaan J Minnaard; Sahar El Aidy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.